Purpose: A hybrid planar-SPECT/CT method for tumor dosimetry in 177 Lu-DOTATATE therapy, applicable to datasets consisting of multiple conjugate-view images and one SPECT/CT, is developed and evaluated. Methods: The imaging protocol includes conjugate-view imaging at 1, 24, 96, and 168 h post infusion (p.i.) and a SPECT/CT acquisition 24 h p.i. The dosimetry method uses the planar images to estimate the shape of the time-activity concentration curve, which is then rescaled to absolute units using the SPECT-derived activity concentration. The resulting time-integrated activity concentration coefficient (TIACC) is used to calculate the tumor-absorbed dose. Semiautomatic segmentation techniques are applied for tumor delineation in both planar and SPECT images, where the planar image segmentation is accomplished using an active-rays-based technique. The selection of tumors is done by visual inspection of planar and SPECT images and applying a set of criteria concerning the tumor visibility and possible interference from superimposed activity uptakes in the planar images. Five different strategies for determining values from planar regions of interest (ROIs), based on entire or partial ROIs, and with and without background correction, are evaluated. Evaluation is performed against a SPECT/CT-based method on data from six patients where sequential conjugate-view and SPECT/CT imaging have been performed in parallel and against ground truths in Monte Carlo simulated images. The patient data are also used to evaluate the interoperator variability and to assess the validity of the developed criteria for tumor selection. Results: For patient images, the hybrid method produces TIACCs that are on average 6% below those of the SPECT/CT only method, with standard deviations for the relative TIACC differences of 8%-11%. Simulations show that the hybrid and SPECT-based methods estimate the TIACCs to within approximately 10% for tumors larger than around 10 ml, while for smaller tumors, all methods underestimate the TIACCs due to underestimations of the activity concentrations in the SPECT images. The planar image segmentation has a low operator dependence, with a median Dice similarity coefficient of 0.97 between operators. The adopted criteria for tumor selection manage to discriminate the tumors for which the absorbed-dose deviations between the hybrid and SPECT methods are the highest. Conclusions: The hybrid method is found suitable for studies of tumor-absorbed doses in radionuclide therapy, provided that selection criteria regarding the visibility and overlapping activities in the planar images are applied.
INTRODUCTION
Peptide receptor radionuclide therapy (PRRT) with 177 Lu-(DOTA,Tyr3) octreotate ( 177 Lu-DOTATATE) is one of the options available for the treatment of neuroendocrine tumors (NETs) and has been shown to result in markedly longer progression-free survival compared to alternative treatments. 1 Patient-specific dosimetry of tumors and organs at risk may potentially be useful to explain responses to treatment and establish dose-effect relationships, and thereby allow for optimization of PRRT on a population or individual level. For PRRT, the main organs at risk are considered to be kidneys and bone marrow. The existence of the absorbed-doseeffect relationships for 90 Y-and 177 Lu-PRRT was recently reviewed by Cremonesi et al. 2 With regard to renal toxicity, there are currently three studies that report dose-effect relationships, of which one concerns 90 Y-PRRT, 3 one 177 Lu-PRRT, 4 and one includes both 90 Y-and 177 Lu-PRRT. 5 Data from two studies 3, 5 were also analyzed in the context of other dose-effect data. 6 For the bone marrow, correlations between toxicity and dosimetry estimates were identified in two studies on 90 Y-PRRT 7, 8 and in four studies on 177 Lu-PRRT. [9] [10] [11] [12] With regard to tumors, correlations between absorbed dose and tumor size reduction were reported in one study on 90 Y-PRRT 13 and one on 177 Lu-PRRT. 14 An additional study on 177 Lu-PRRT 12 observed a reduction in the level of the biochemical marker chromogranin A that correlated with tumorabsorbed dose in a subset of patients. These results are encouraging and indicate the possibility of future treatment optimization as well as individualization of PRRT based on dosimetry-guided treatment protocols. However, more research is needed to investigate, verify, and establish possible dose-effect relationships in larger patient cohorts. A prerequisite for such studies is that dosimetry is performed on an individual patient basis.
As shown by Cremonesi et al. 2 , reported data on the absorbed dose per amount of administered activity for tumors show a considerably larger variation between patients than data for kidneys and bone marrow. In a recent literature summary by Eberlein et al. 15 , individual tumorabsorbed doses between 0.1 Gy GBq À1 and 56 Gy GBq
À1
were reported, which is a substantial range. The observed variability may be true in the sense that it reflects a heterogeneous disease where, for example, somatostatin receptor density, binding avidity, internalization, and degradation can theoretically vary substantially between patients. Any and all of these could affect the absorbed dose, but it may in part also be a result of uncertainties associated with the different methodologies used for dosimetry. Generally speaking, tumor dosimetry in PRRT is a more challenging task as compared to dosimetry for solid normal organs, due to highly variable tumor volumes, shapes, and activity concentrations in surrounding tissues. Calculated absorbeddose values may therefore be sensitive to the imaging modality used (planar or SPECT imaging), settings in the tomographic reconstruction, any filtering employed, and the strategies used for image segmentation and partial volume correction. Validation of the dosimetric method used is thus essential in order to produce absorbed-dose estimates that are comparable between centers, in particular when investigating dose-effect relationships.
In an ongoing clinical trial of 177 Lu-DOTATATE PRRT, conducted at two Swedish university hospitals (www.clinicaltrials.gov, NCT01456078), patients are imaged during each therapy cycle using a combination of anterior-posterior wholebody imaging at four time points and one SPECT/CT. This imaging protocol offers a compromise between the axial coverage of whole-body images and the three-dimensional information of SPECT/CT. The acquired images are currently used for renal dosimetry, using a hybrid planar-SPECT/CT dosimetry technique, 16 in which the shape of the time-activity curve is determined from the planar images and the activity concentration value, derived from SPECT, is used to rescale the curve to absolute units. In addition to kidneys, tumors are also detectable in the acquired images, and tumor dosimetry could therefore be performed retrospectively, provided that a reliable tumor dosimetry method was available.
Hybrid imaging techniques have been presented and applied earlier [16] [17] [18] [19] [20] [21] [22] [23] and include methods of varying complexity, from separate analysis of planar and SPECT images 17 to more sophisticated methods where the SPECT/CT is used to correct for overlapping activity uptakes. 19, 21 A few studies include evaluation of the dosimetric accuracy and uncertainty, 19, [23] [24] [25] mainly using phantom studies. Overall, the results show that hybrid methods perform better than methods based only on planar images and are generally comparable to purely SPECT-based methods, albeit with some losses of accuracy and precision that are dependent on which organ is analyzed and which radiopharmaceutical is used. Mainly, it is the quantitative accuracy for normal organs that has been evaluated, while the suitability of hybrid methods in the context of tumor dosimetry is less investigated.
An additional and often unaddressed source of uncertainty is associated with the delineation of tumors in images. Manual segmentation suffers from intra-and interoperator variability 26, 27 and entails a substantial workload, in particular when there are multiple tumors, each of which needs to be evaluated in the time sequence of images acquired after each administration. Simple threshold-based segmentation methods offer smaller workloads and less operator dependence, but the result is sensitive to local image contrast and noise. 28, 29 Other automatic or semiautomatic segmentation techniques may here offer advantages over manual and threshold-based segmentation.
The aim of this work is to develop and evaluate a method for tumor dosimetry based on hybrid planar-SPECT/CT image data. The method employs semiautomatic active-contour segmentation techniques applied to quantitative planar and SPECT images. The segmentation method for planar images is based on the active-rays technique 30 originally developed for real-time contour tracking in photographic image sequences, and has, to the best of our knowledge, previously never been applied to nuclear medicine images. This work thus also includes a detailed description of the segmentation method.
MATERIALS AND METHODS

2.A. Patient image data
Image data for six patients were used, acquired during one 177 Lu-DOTATATE therapy cycle per patient (Table I) . For each patient, four planar gamma-camera images were acquired as well as three (1 patient) or four SPECT/CT images (five patients). The images were acquired at nominally 1, 24, 96, and 168 h post infusion (p.i.) of 7400 MBq of 177 Lu-DOTATATE. Image systems used were a Discovery VH SPECT/CT (General Electric, Milwaukee, WI, USA) (three patients), and a GE Discovery 670 (GE Healthcare) (three patients).
Acquisitions were performed using medium energy general purpose (MEGP) collimators and 15% (Discovery 670) or 20% (Discovery VH) energy windows centered at 208 keV. Planar anterior-posterior images were acquired in 256 9 1024 matrices with a pixel size of 2.21 9 2.21 mm 2 . The whole-body scan speed was 20 cm min À1 at the first measurement time point and 10 cm min À1 at the later measurements. Projections were acquired in 60 angles over a full rotation in 128 9 128 matrices with a pixel size of 4.42 9 4.42 mm 2 (Discovery 670) or 4.02 9 4.02 mm 2 (Discovery VH), and 45 s per projection. Tumor selection was made based on the visual appearance in planar and SPECT images. To enable simultaneous image analysis, a graphical user interface was developed in which the planar and total intensity projections of the SPECT images were first rigidly coregistered. The two-dimensional planar and three-dimensional SPECT images were then displayed beside each other, and a synchronized crosshair allowed for tumor identification in the two images (Fig. 1) .
Given the possible interference from overlapping activity uptakes in the planar images, a set of criteria was adopted for tumor selection with regard to the suitability for analysis (Table II) . For the method-development part of this work, a total of 19 tumors were selected, of which 14 clearly met all TABLE I. Details on patient treatments, image acquisitions, and identified tumors. The three columns under tumor selection show the number of tumors included in the method-development stage of this work (A), the number of additional tumors included in the criteria-assessment stage (B), and the total number of tumors seen in each patient (Total).
Pat#
Adm The first planar image of patient 3 was not used in order to obtain comparable time-activity data for the hybrid and SPECT methods. An additional set of tumors, with generally less suitable characteristics, was examined to assess the importance of the selection criteria. This part of the work included 19 additional tumors, of which three were classified as suitable, three as possibly suitable, and 13 were classified as unsuitable, that is, they clearly did not meet criteria 2 or 3. Criterion 1 was maintained for this complementary analysis. Table I includes the number of tumors selected for the method-development part, the criteria-assessment part as well as the total number of tumors that were detectable in each patient.
2.B. Image simulations
Three computer phantoms from the XCAT family 31, 32 representing the anatomies of two females and one male were used to obtain Monte Carlo simulated planar gamma-camera and SPECT images. The phantoms were voxelized with a voxel size of 2.5 9 2.5 9 2.5 mm 3 , and a pharmacokinetic compartment model was used to obtain activity concentration curves for all phantom regions. 33 Each phantom contained two or three tumors (eight in total) with volumes between 2.75 ml and 45.5 ml and were located in the liver and abdomen. Tumor locations are illustrated in Brolin et al. 33 . SPECT and planar images were simulated using the SIMIND Monte Carlo program 34 for the clinically used time points after injection. The simulated camera was equipped with an MEGP collimator and a 5/8 in crystal, and settings as for the Discovery 670 system were used. Simulations were performed with a high number of histories in order to obtain essentially noise-free images. The image values were then rescaled to correspond to an initial infusion of 7400 MBq with activity excretion according to the compartment models and acquisition times corresponding to those clinically used. The images were given realistic noise levels by replacing each pixel value with a pseudorandom number from a Poisson distribution with expectation value set to the simulation-derived number of counts for that pixel.
2.C. Image-based activity quantification
The CT scout image and the planar gamma-camera images were processed using a pixel-based quantification method including attenuation and scatter correction. 35, 36 For each pair of conjugate-view images, the process yielded one image of the planar activity distribution with pixel values corresponding to activity. The acquired SPECT projections were reconstructed using an ordered subset expectation maximization (OS-EM) algorithm. Two reconstructions were performed for each set of projections, one including corrections for attenuation and scatter only (AS), and one also including distance-dependent resolution (ASR), where the effective source scatter estimation method 37 was used for scatter correction for both methods. Reconstructions were performed with six angles per subset (i.e., ten subsets) and 1-20 iterations (AS) and 1-100 iterations (ASR). To optimize the reconstruction parameters, an evaluation of the convergence of the estimated mean activity concentration in tumor volumes of interest (VOIs) as a function of the number of iterations was performed in the patient SPECT images.
2.D. Planar image segmentation
A semiautomatic method based on active contours and active rays 30, 38 was implemented in the IDL programming language (version 8.5, Exelis Visual Information Solutions, Boulder, Colorado). The method performed a polar resampling of image values in a region centered over the object of interest, thus reducing the delineation task to the determination of the contour radius as a function of angle.
2.D.1. Polar resampling
The first step was to determine a center point ðx 0 ; y 0 Þ, which in this work was specified by the user within the tumor boundary. The next step was to sample the two-dimensional image I(x,y) along N evenly distributed lines radially outward from the center point ðx 0 ; y 0 Þ, which produced a polar image P(k,n) according to
n ¼ 0; 1; 2; . . .; M À 1;
where k denotes the radial line number, h k is the angle determining the direction of a radial line, M is the number of samples made along each radial line, r n is the distance from the center point ðx 0 ; y 0 Þ to a particular sampling point, Dr is the radial sampling interval, and P(k,n) is the image obtained by the radial resampling. The parameters x, y, k, n, r n , Dr etc., are expressed in lengths of the spacing between pixels, and the image values of I(x,y) and P(k,n) are known at integer TABLE II. Adopted criteria for tumor selection.
1. The tumor is within the SPECT field of view at all time points, with a margin of five axial slices from the upper and lower edges to avoid influence from edge image artifacts.
2. There is no major overlap in the planar images from other organs or tumors with high activity uptake, as determined by visual inspection of the SPECT/CT image along the anterior-posterior direction at the tumor location (see Fig. 1 ).
3. The tumor uptake and its boundaries are clearly identifiable in the planar images at visual inspection ( Fig. 1 ).
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coordinates. Bilinear interpolation was used to determine values of I at noninteger coordinates. The polar resampling is illustrated in Fig. 2 .
2.D.2. Delineation
An iterative method similar to so-called snakes 38 was used to obtain a path following a contour in the polar image P(k, n). The path consisted of a set of points ðk; l k Þ where the k-coordinate corresponded to the k'th column in the image P(k, n) that in turn corresponded to the radial line of number k, and l k Á Dr was the radial coordinate of the path for that radial line.
The segmentation method iteratively updated the radial coordinates l k of the path until convergence was reached, using the equation
where l i k is the radial coordinate for the ith iteration, F E ðk; l i k Þ is an external force field acting on the contour, F I ðl i k Þ is an internal force of the contour, d is a step length, and w E and w I are weighting factors for the external and internal forces, respectively.
Convergence of the path was determined by the criterion
where T is a predefined threshold. The external force field was calculated using the equations
U E ðk; nÞ ¼ sgn DP r ðk; nÞ Dn Á DP r ðk; nÞ Dn 2 ;
P r ðk; nÞ ¼ Pðk; nÞ G r ;
where sgn(Á) is the signum function, ⊗ denotes discrete convolution, U E is an external energy field related to the gradient in the polar image, c is a positive normalization coefficient with a value calculated such that the largest value of jF E ðk; nÞj is 1, and P r ðk; nÞ is the result of a discrete convolution between P(k, n) and a Gaussian kernel G r with standard deviation r. The difference operator, D, in 6 and 7 was implemented using a discrete convolution with a 3 9 3 kernel that represented differences in the n-direction. Linear interpolation was used to evaluate values of F E ðk; nÞ at noninteger coordinates in 4. An internal energy E I was defined for the curve as
where a and b are weighting factors, and the two sums represent discrete approximations of the integrals of the squared first-and second-order derivatives of l k as a function of k.
Use of the b-term was found to be sufficient for obtaining smooth contours during the tuning of the parameters, and a was thus set to 0 as the minimization of E I would otherwise favor the solution l kþ1 ¼ l k 8k, corresponding to a circle. Implementation of 9 was made following
The parameter l k was assumed to be periodic in k with period N, thus assuring that the internal force could be calculated near the k = 0 and k = NÀ1 end points. This assumption was natural, since a closed contour with the same radius for h k ¼ 0 and h k ¼ 2p was forced.
The contour search was performed in a coarse-to-fine manner (so-called scale space) and was initiated with a standard deviation, r start;auto , for the Gaussian kernel, G r , and a straight path ðk; l k Þ with l k ¼ l start 8k. This initial contour corresponded to a circle with radius l start Á Dr in Cartesian coordinates. Alternatively, the method could be initialized with a path ðk; l k Þ created by a user and with a lower initial value r start;user for G r . Once convergence had been reached, the contour search was repeated with r decreased by r decrement and with the path ðk; l k Þ from the previous scale as the starting path in 4. This process was repeated until a lower limit r stop of the standard deviation was reached. Once convergence had been reached for the finest resolution level, ðk; l k Þ was converted from the polar representation to a set of Cartesian coordinates ðx k ; y k Þ using the equations
In addition to the contour (x,y), two additional contours constituting an inner and outer contour of a background region of interest (ROI) were created. These were determined by expanding the contour (x,y) radially outward from ðx 0 ; y 0 Þ by two fixed distances. The ROIs and background ROIs were generated from the contours by creating binary masks with the same dimensions as f(x,y).
The planar segmentation method is summarized in supplemental figure S1 . The values used for the segmentation method parameters are listed in Table III .
2.E. Planar image ROI analysis
For the planar images, five methods for assessing the tumor time-activity data were evaluated, henceforth termed Aver, AverC, Max5, Max5C, and Cursor, where the extension C indicates inclusion of background correction (Table IV) . In Aver, the mean pixel activity in the ROI was determined, and in AverC, this value was subtracted by the mean pixel activity in the background ROI. The method Max5 instead used the mean value of the five highest pixel values in the ROI, and in Max5C, background subtraction was included. The method Cursor used the mean of the fives pixels closest to the center point selected by the operator, without background subtraction. The motivation for including these latter alternatives was that accurate quantification of the total tumor activities was not necessary, since only the shape of the curve was estimated from the planar images. A small central ROI could thus be suitable, assuming that the influence of superimposed peritumoral activity then becomes smaller and thus its effect on the shape of the estimated time-activity curve.
2.F. SPECT image segmentation and activity quantification
A Fourier-surface-based method described in Gustafsson et al. 29 was used for SPECT image segmentation. In that study, it was found that the best results in terms of estimated volume and activity concentration recovery were obtained when delineating the tumors in SPECT images reconstructed with AS corrections, and then applying the resulting VOIs to SPECT images reconstructed with ASR. This methodology was thus used in the current work, such that segmentation was performed on the AS images reconstructed with eight iterations, while the tumor mean activity concentrations were estimated in the SPECT images reconstructed with 40 iterations and ASR.
As a result of different count levels, in the tumor itself and in surrounding tissues, segmentation of the different time point images produced slightly different VOIs and volumes. As NETs are slowly responding, this was not likely an effect of real tumor change but uncertainty in the volume estimation. Since for this work, the main purpose of the SPECT/CT images acquired at four time points was to serve as reference data in the evaluation of the hybrid dosimetry method, it was considered important to reduce the influence of inconsistent VOI delineation upon activity concentration estimates in SPECT. Thus, the VOIs drawn on the image acquired at 24 h p.i. were used for all time points. Since the SPECT images from the different time points were not coregistered, a procedure was developed where each of the images acquired at 1, 96, 168 h p.i. were segmented, and the VOIs from the image acquired 24 h p.i. were then translated so that their centers of mass coincided with the centers of mass of the corresponding VOIs being replaced.
A recovery coefficient (RC) was applied to take resolution-induced spill out into account, where RC curves were parameterized as described in Gustafsson et al. 29 . Separate RC curves were determined for the patient and simulated images, where SPECT acquisitions of spheres of different radii were used to determine the RC curve for the patient images, while corresponding Monte Carlo simulations were used for the simulated images. For the simulated images, where both measured and reference volumes were available, the estimated volumes were used for calculation of the RC, since the purpose was to mimic the patient image processing procedure.
2.G. Curve fitting and absorbed-dose calculation
Altogether the analysis of planar and SPECT images yielded six datasets, of which five sets of time-activity data were from the planar ROI analysis methods and one set of activity concentration data was from SPECT only. For curve fitting, a function composed of a mono-exponentially decreasing tail and an initial part described as a quadratic polynomial was used (see supplementary material 1.2). The exponential function was fitted to the three last data points (24 h to 168 h), and the quadratic part was then analytically calculated so that the combined function was continuous and differentiable at the second time point (24 h) where the transition between the two curve segments occurred. For one of the patients, the SPECT/CT at 1 h was not available, and the exponential curve without the initial quadratic part was instead used for the whole time range. Hybrid activity concentration curves were determined by scaling the planar-derived curves to the SPECT activity concentration at 24 h, following
where C Hybrid ðtÞ is a hybrid time-activity concentration curve, A Planar ðtÞ is a planar-derived curve, C SPECT ðt SPECT Þ is the activity concentration in the SPECT image acquired at time t SPECT (nominally 24 h p.i.), and R(V) is the recovery coefficient, with tumor volume V estimated from the SPECT VOI.
The time-integrated activity concentration coefficient (TIACC) from 0 h p.i. to infinity was determined by analytical integration. The mean tumor-absorbed dose, D, was calculated by the assumption that the kinetic energy of all emitted electrons was locally absorbed, 39 according to
whereC is the TIACC, E( 177 Lu) is the mean emitted electron energy per decay for 177 Lu, and q is the density of the target tissue, which was assumed to be 1.0 g ml À1 .
2.H. Evaluation of SPECT and hybrid methods
For the simulated images, the obtained TIACCs were evaluated against the reference TIACCs defined in the simulations, both for the hybrid and the SPECT methods. The error introduced by the estimation of the activity concentration in the SPECT images was also investigated by creating separate datasets that were normalized to the reference activity concentrations at 24 h p. For patient images, the SPECT-derived curves were used as reference for evaluation of the hybrid data. The comparison was made in terms of effective half-lives, TIACCs, and absorbed doses and was limited to the 19 tumors selected for method development (Table I ). The relative difference of a TIACC was calculated as ðC Hybrid ÀC SPECT Þ ÁC À1 SPECT , wherẽ C Hybrid andC SPECT are the TIACCs of a hybrid and the SPECT method, respectively. Due to the proportionality between D andC in 14, the relative difference in absorbed dose was identical to the relative difference in TIACC.
After the curve fitting to the patient time-activity data, the quality of the fit, ɛ, was evaluated according to
where y m ðt i Þ is a measured value at time t i , y f ðt i Þ is the corresponding value of the fitted curve, and S is the number of points used for the curve fitting (S = 3). The first measurement point (1 h) was not included in the sum, since the difference was there zero by definition. Moreover, to assess the importance of the first part of the activity concentration curve in the calculation of the absorbed dose, the area under the curves from the 24 h imaging time to infinity was calculated and compared to the area under the curve when integrated from 0 h.
2.I. Operator dependence of the planar segmentation and time-activity curves
The operator dependency of the planar segmentation method was evaluated. Two operators were given identical data, consisting of quantitative planar and SPECT images, as well as SPECT VOIs. They were asked to identify the tumors in the planar images that corresponded to those delineated in the SPECT images and to initialize the planar image segmentation. The resulting ROIs were compared using the Dice similarity coefficient, 40 DSC, as given by
where X and Y are pairs of operator ROIs and |Á| denotes the cardinality of a set. The effective half-lives of pairs of curves from both operators were compared using a Bland-Altman analysis. 41 
2.J. Assessment of the tumor selection criteria
The question of whether a hybrid dosimetry method was contraindicated for tumors that did not meet criteria 2 or 3 in Table II was assessed. This was done by analyzing an additional set of 19 tumors (Section 2.A, Table I ) with the hybrid Max5 method. In a few of the tumors classified as unsuitable the semiautomatic segmentation method failed, and manual segmentation was then used as a complement. The total set of 38 tumors were classified according to the developed criteria (Table II) and the estimated absorbed doses from the hybrid and SPECT-based methods were compared using Bland-Altman analysis.
RESULTS
The hybrid method, including the different variants of background subtraction, was evaluated based on the 19 tumors in the six patients (Table I) , and the eight tumors in the three simulated phantoms. The validity of the selection criteria and the overall performance of the Max5 hybrid method were evaluated based on the, in total, 38 patient tumors (Tables I and II) . Figure 3 shows how the estimated activity concentration in tumors converge as a function of number of iterations, for patient images acquired 24 h and 168 h p.i. reconstructed with ASR corrections. A smaller variability in the convergence rate is obtained for the 24 h images compared to the 168 h images, which is in line with a lower signal-to-noise ratio for later time points. The tumor mean values in the SPECT images reconstructed with AS corrections converge after approximately four to five iterations (data not shown).
3.A. Optimization of SPECT reconstruction
3.B. Quantification of dosimetric variables
Two examples of hybrid-and SPECT-derived curves are shown in Fig. 4 . The effect of background correction is particularly manifested in the 1 h data points, where the hybrid methods that do not include background correction yield higher values.
The quality of the fits, ɛ, for all patient-tumor curve are listed in Table V . The analysis methods including background correction (AverC and Max5C) produce a slightly higher variability in the measured time-activity data, while methods without background correction produce data to which the fitted curve conforms better. To put data in Table V in perspective, ɛ for the curves in Fig. 4(a) are in the 1.7%-2.3% range, while for Fig. 4(b) , the corresponding results are 0.2%-1.1%.
The fractions of the patient-tumor TIACCs that originate from the 24 h data point and onward, compared to the TIACC obtained by integration from time zero, are for SPECT data obtained to 83%, 87%, and 89% (10th, 50th, and 90th percentiles). For hybrid and using the Max5 method, the corresponding values are 81%, 85%, and 88%, respectively, and similar fractional TIACCs are obtained for the other hybrid methods.
Patient results of the hybrid and SPECT-based methods are shown in Table VI These values are identical to the absorbed-dose differences in Table VI . There is no clear dependency on the tumor volume; however, there appears to be a variation between patients, where for five patients, the differences are within 15%, while for patient 4, an underestimation down to À30% is obtained.
For the five hybrid methods, the mean and standard deviation of the TIACC differences are À6 AE 8% (Aver), À5 AE 11% (AverC), À6 AE 8% (Max5), À5 AE 10% (Max5C), and À7 AE 8% (Cursor). The background correction included in AverC and Max5C thus has little effect on the mean difference, but tend to result in a slightly increased standard deviation. Figure 6 shows TIACC differences for the simulated data where the phantom reference values are used for comparison, and the SPECT-based data are also included. Data are only shown for hybrid methods Max5 and Max5C, while the other methods produced similar results. Results from the two datasets in Fig. 6(c) , that is, SPECT with different normalization, show that the underestimations obtained for volumes below 10 ml are caused by an underestimated activity concentration from the SPECT images. For the hybrid methods [Figs. 6(a) and 6(b)] and tumor volumes above 10 ml, there is a tendency that methods without background correction (a) produce a small underestimation that remain when normalizing to the reference activity concentration at 24 h p.i. However, the differences between the hybrid methods are subtle.
3.C. Operator dependence
The Dice coefficients obtained from the patient images and all time points are shown in Fig. 7(a) . The four lowest DSCs in Fig. 7(a) originate from the same tumor at the four imaging time points. The low DSCs are in this case due to a differing tumor identification by the operators, of two separate, but overlapping patterns in the planar images. The 5th and 6th lowest DSCs originate from delineation in images acquired approximately 1 h p.i. The DSCs are generally lower for the first imaging time with a median DSC of 0.936, whereas the median DSC are 0.979, 0.970, and 0.965 for the 24, 96, and 168 h images, respectively. A lower DSC for the first images is a reasonable result, since the background activity is high and tumors have a lower uptake shortly after infusion, causing poor image contrast.
A comparison of the effective half-lives obtained from the two operators is presented in Fig. 8 . No major systematic difference between the operators' results can be discerned. The best agreement is obtained for the Max5 method, whereas poorer agreements are obtained when background correction is included, or when the mean ROI value is used. Figure 9 demonstrates the results of applying the Max5 hybrid method on patient tumors classified as suitable, possible suitable, or unsuitable for hybrid analysis. The mean and standard deviations of the relative differences in absorbed doses are À6 AE 8% (suitable), À7 AE 11% (possibly suitable), and À11 AE 15% (unsuitable).
3.D. Assessment of the tumor selection criteria
DISCUSSION
In this work, a planar-SPECT hybrid method for tumor dosimetry based on semiautomatic segmentation is developed and evaluated. The main objective was to obtain a method with low operator dependence and a high accuracy in estimated TIACCs and absorbed doses. Generally speaking, achieving accurate tumor absorbeddose estimates in PRRT is challenging. Published data on tumor absorbed doses in 177 Lu-DOTATATE PRRT reflect a wide range, as recently summarized by Eberlein et al. 15 . Mean and median values of the absorbed dose per administered activity calculated over groups of patients of between 2.6 Gy GBq À1 and 9.7 Gy GBq À1 have been reported. 12, 14, 20, 24, [42] [43] [44] These were estimated using various methods involving planar images, 24, 42, 44 SPECT/CT images, 12, 14, 24, 43 or a combination of planar and SPECT/CT images. 20, 24 In this work, the mean value obtained is 3.9 Gy GBq À1 when estimated using the SPECT only method, and 3.6 Gy GBq À1 when using the Max5 hybrid planar-SPECT/ CT method. The reasons for the differences in reported absorbed-dose values are difficult to elucidate and may be due to methodological differences or biological differences related to different primary tumor origins, the disease stage, the evaluated treatment cycle number, or the location of the tumors selected for evaluation. Most publications did not report the primary tumor origin; 24, [42] [43] [44] Garkavij et al. 20 included mainly small intestinal NET (13 of 21 pts), the remaining being pancreatic, thymic, rectal, and lung NET; Ilan et al. 14 only included pancreatic NET larger than 2.2 cm in diameter; and Del Prete et al. 12 mainly included small intestine (17 of 36 pts) and pancreatic NET (10 of 36 pts).
The primary tumor origins in the current study are shown in Table I . In order to rule out differences in absorbed-dose estimates that stem from the methodology and thus ensure reliability, systematic method development and evaluation are deemed necessary.
There are difficulties associated with determining the shape of time-activity curves in planar images where the pixel values represent an integration of the activity distribution in the anterior-posterior direction. This yields a superposition of tumor and peritumoral activities which means that the values in tumor ROIs and the resulting time-activity curves represent a mixture of both. However, tumors generally have higher uptake and longer biological half-life than surrounding tissue, and so their activity may dominate the measured activity in a pixel. Thus, although tumors are sometimes small, investigation of the possibility of estimating their time-activity curve shapes from planar images was justified.
A potential issue with the adopted approach is the assumption of homogeneous pharmacokinetics in the entire tumor, whereas in reality, it could vary within the tumor. 45 However, this is an issue common to any method that estimates the time-activity curve based on a part of the organ or tumor. For this work, the tumor volumes were comparably small. The limited spatial resolution and particular the nonexistent spatial resolution in the anterior-posterior direction in planar images are believed to limit the possibility to analyze the variation of the pharmacokinetics within tumors. However, the operator dependence seen for the Cursor method [ Fig. 8(e) ] could potentially be related to this problem, and points at the need of a consistent segmentation strategy.
For time-activity curve fitting, a function with a quadratic polynomial segment followed by a mono-exponential segment was used. This choice was motivated by observed variations in the measured value at the first imaging time, acquired around 0.5-1.2 h after administration, when the surrounding plasma activity is still comparatively high, thus favoring a decoupling of the first data point from the curve fitting to the remaining data. This function provides a good fit (Table V) , while also preventing variability in the first data point from influencing the curve after 24 h p.i. The contribution to the total TIACC from 0 h to 24 h was found to be moderately low (approximately 15%), indicating that the choice of function in this interval has a low effect on the estimated total absorbed dose, which mainly depends on the integration of the curve from 24 h p.i. and onward. Automated delineation of tumors in planar gamma-camera images is a relatively scarcely researched area. The activerays-based method developed and used herein was found easy to use and produced reasonable results. Evaluation of the segmentation against reference objects was not performed and was not considered motivated in view of the application. While in principle outermost contours of two-dimensional projections of tumors could be obtained and used for evaluation, the primary purpose of the segmentation was to produce values for estimation of time-activity curves rather than the total activity. Additionally, the outermost contour may not necessarily be the ROI that produces the most correct timeactivity curves, since the tumor periphery may be more affected by the superposition of over-and underlying activity. This means that consistent delineations are still desirable, but ROIs corresponding to the full extent of the tumors are not necessarily required. The aspects deemed important for the segmentation was therefore ease of use, the ability to produce delineations that appeared credible at visual inspection, and most importantly, to yield accurate time-activity curves. The operator study was undertaken to assess the influence of the initialization, that is, the center coordinate for the polar sampling and the initial contour. The obtained DSC values in Fig. 7(a) indicate that the method has a modest to low dependence on the operator initialization, and Fig. 8 suggests that there is no major systematic difference in effective half-life between the operators.
Background subtraction is a common compensation method for peritumoral activity in planar images. Assuming that tumors have longer biological half-lives than the background tissue, the influence of the peritumoral activity is a reduction in the estimated effective half-life, and a successful background correction should therefore increase the effective half-life. Indeed, results from the simulated images in Fig. 6 indicate that methods that include background correction produce slightly higher TIACCs, and Table VI shows a small increase in half-life for the patient images (on average 90 h with and 87 h without). However, this effect is not clearly observed in terms of the TIACCs in the patient images (Fig. 5) , where differences to a larger extent are dominated by an increased standard deviation when including background correction. The different conclusions on the value of background correction, when evaluated using patient or simulated data, are a result of the less complex background distribution in the simulated images. Thus, although great effort has been put into the development of representative test material in the form of pharmacokinetic phantoms (Brolin et al. 33 ), further phantom development would be required to fully mimic the tumor burden and nonhomogeneous activity distribution of real patients.
The results of the operator study (Fig. 8) show that the methods that include background correction yield a higher dispersion than methods without. Furthermore, the methods based on the five highest pixel values in the ROIs show less dispersion than the methods based on the entire ROI, with the Max5 method having almost no operator dependency.
For the SPECT image reconstruction, the rate of convergence in estimated activity concentration depends on the image distribution and is of importance when the activity distribution around the tumors differs between the time points. During the initial stages of this study, SPECT reconstructions were performed using eight iterations for both AS and ASR. However, for ASR, a variability in the estimated activity concentrations was obtained, as seen in Fig. 3 at eight iterations where the rate of change between iterations is not negligible. For the subsequent work, 40 iterations was therefore applied, in order to achieve convergence.
From Figs. 6(a)-6(b), based on simulated data, it is seen that there is an underestimation of the TIACC for tumors smaller than 10 ml. Normalization to the reference activity concentrations at 24 h p.i. markedly reduces this underestimation, indicating that it is mainly caused by the activity concentration determination from the SPECT images, in consistency with the results in Gustafsson et al. 29 . The remaining underestimation is due to the estimation of the effective half-life. The results from the patient images in Fig. 5 indicate that the hybrid method yields TIACCs that on average are 6% below the SPECT-based method, with a standard deviation of 8%-11% for the TIACC differences. It is worth noting that the findings from the simulation studies could not have been obtained from patient data due to the impracticality of ground truth measurements. The results on the operator study could not be obtained in simulated data. The combination of patient and simulated data used herein has thus been found valuable.
The absorbed-dose calculation is in this work performed based on the assumption that the electron energy is absorbed locally in the voxel it is emitted. This calculation method was chosen since the main focus is the performance of the hybrid method. As long as only self-absorbed doses are considered, then the absorbed-dose rate curves have the same shape as the time-activity concentration curves, and the relative differences in TIACC and absorbed doses are identical. This assumption should be reasonable, since tumors generally have a high activity uptake compared to their surroundings, and the yield of high-energy photons for 177 Lu is low, implying that photon cross-dose from neighboring voxels should constitute only a small fraction of the total absorbed dose.
Results of our hybrid method can be compared to the results of existing publications. He et al. 19 evaluated residence-time estimations in normal organs in a phantom population with planar, hybrid, and pure SPECT methods for 111 In ibritumomab tiuxetan. For the smaller solid organs, their hybrid approach yields residence time errors that are approximately 10% points below those obtained from a SPECTbased method. Although that study does not address the same radiopharmaceutical, their results are comparable to the trends and values found in this study (Fig. 5) . Berker et al. 23 also show that a hybrid method produce absorbed dose estimation errors of within 14% for most organs. However, no trends of over-or underestimations can be discerned in their study. Kupitz et al. 24 evaluated 177 Lu-DOTATATE dosimetry with planar, hybrid, and pure SPECT methods for normal organs and tumors in patients. Higher absorbed doses were generally obtained with the hybrid method compared to pure SPECT. The findings of generally higher absorbed doses from the hybrid method are not in line with the results in this work or most results in He et al. 19 , and reasons for these differences are difficult to determine.
A total of 17 tumors were found to meet the three criteria and were classified as suitable for dosimetry (Table II) . This is far from the 65 tumors that were identified in the planar and SPECT images (Table I) . In many cases, the reason for exclusion was that it was difficult or even impossible to make delineation in the planar images because of low contrast or a unclear tumor border, while in some cases, prominent overlapping activities were present. The selection criteria were developed as a means to guide in the selection of tumors for analysis, and Figure 9 shows the effect of applying these criteria. It appears that some of the tumors deemed unsuitable could have been successfully analyzed. However, the criteria managed to discriminate the five tumors with the lowest agreement, which is considered most important. This shows that some criteria are required when selecting tumors for analysis with a hybrid method. The use of more advanced hybrid methods capable of overlap correction using information from SPECT images and VOIs 18, 21 could potentially decrease the need for such restrictions. However, the accuracies of such methods in a real-world setting may depend on the accuracy of image registration, 18, 19 which may be challenging, in particular for small tumors.
It is reasonable to question whether or not it is relevant to base a patient's tumor dosimetry on results obtained from a selection of tumors rather than the whole tumor burden, and whether the selection is representative of the whole. A parallel can be drawn to how treatment efficacy is commonly evaluated in oncology using the Response Evaluation Criteria in Solid Tumors (RECIST). 46 In short RECIST consists of following the development of the size of a patient's tumor(s) from baseline (before treatment initiation), during, and after the completion of therapy. A maximum of two lesions per organ and five lesions in total, representative of all involved organs, are identified as target lesions and the remaining sites of disease are followed as nontarget lesions. Target lesions must be measurable, that is, be larger than 10 mm in diameter on a CT or MR image. The same target lesions are systematically measured at each radiological evaluation, and the evolution of the nontarget lesions evaluated more globally. The RECIST criteria have been the basis for the evaluation of treatment efficacy, especially within clinical trials for over 15 years. The RECIST system is imperfect, in part because of being based only on a selection of tumors and partly because it does not always adequately reflect tumor biology. Despite these flaws, it has proven to be useful and correct in most situations, it is clinically validated, and it is an acceptable compromise between the perfect and the feasible. The same reasoning can be applied to the systematic selection of tumor lesions in the present analysis -it makes tumor dosimetry feasible. A difference in relation to the RECIST criteria is, however, that in this analysis, the image features govern the tumor selection, whereas for RECIST, the tumors with the largest diameters that are reproducibly measurable are selected for evaluation. Whether our criteria are also sufficiently correct on a larger scale is still to be proven and is beyond the scope of this initial method development. As long as the criteria do not introduce a selection bias with regards to tumor biology, there is no reason to believe that we are introducing a systematic error in the analysis.
CONCLUSION
Tumor dosimetry in 177 Lu-DOTATATE PRRT with a hybrid planar-SPECT/CT method is applicable when criteria regarding visibility and overlapping activity are applied, with results that are mainly consistent with a SPECT/CT-based approach. Evaluation based on simulated data shows that for tumors larger than 10-15 ml, the estimated TIACCs are within 10% of the reference values, while for smaller tumors, underestimations of approximately 30% are obtained, mainly due to the SPECT/CT activity concentration estimation. The effective half-life estimated from planar images is to some degree affected by peritumoral activity, resulting in an underestimation of the absorbed dose, with deviations of approximately À6% AE 8% obtained as compared to a SPECT/CTbased method. The planar segmentation method has been found easy to use with a low operator dependence. Results obtained are encouraging for the possibility of performing tumor dosimetry in radionuclide therapy, when there are numerous sites in each patient that need to be delineated in the sequences of images acquired during each cycle.
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